PRKAA1 and metabolic dysfunction-associated steatotic liver disease: serum ALT and AST levels were significantly higher in the NAFLD + AMPK-IN-3 group compared to the NAFLD + DMSO group (P < 0.001), indicating aggravated liver damage following AMPK inhibition.